COMP <GO>
DRMA vs NRSN // DIVIDEND YIELD & FCF PAYOUT SAFETY
Dermata Therapeutics Inc. (NASDAQ) VS. NeuroSense Therapeutics Ltd. (NASDAQ) • 15-METRIC TALLY: DRMA 2
— NRSN 0
■ METRIC PARITY
LAST: $0.84 (-3.84%) • MKT CAP: $4.2M
dividend-safety
0.00%
LAST: $2.13 (-9.75%) • MKT CAP: $4.0M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DRMA VS. NRSN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DRMA | NRSN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 1/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.9 | 21.6 | +18.27 | DRMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.2M | $4.0M | $127.4K | DRMA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DRMA REV | NRSN REV | DRMA GROSS % | NRSN GROSS % | DRMA FCF | NRSN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$7.8M | -$7.7M |
| FY 2024 | $0 | $0 | — | — | -$11.2M | -$10.1M |
| FY 2023 | $0 | $0 | — | — | -$6.4M | -$8.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DRMA // BETA —
NRSN // BETA —